Market Cap 2.50B
Revenue (ttm) 233.18M
Net Income (ttm) -321.55M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -137.90%
Debt to Equity Ratio 0.00
Volume 2,008,068
Avg Vol 2,204,878
Day's Range N/A - N/A
Shares Out 89.14M
Stochastic %K 76%
Beta 0.83
Analysts Strong Sell
Price Target $35.93

Company Profile

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport di...

Industry: Biotechnology
Sector: Healthcare
Phone: 888 969 7879
Address:
3611 Valley Centre Drive, Suite 300, San Diego, United States
DeadInvestor
DeadInvestor Oct. 27 at 4:14 PM
$TVTX Average analyst estimates are $104.6 million. Whats everyone’s view here? It would be nice for TVTX to beat estimates here.
0 · Reply
DeadInvestor
DeadInvestor Oct. 24 at 4:39 PM
$TVTX What value do we assign to this Chugai Japan deal (Renalys) royalties?
0 · Reply
Drashkawisha
Drashkawisha Oct. 21 at 11:25 AM
$TVTX hidden gem
0 · Reply
Dimon11
Dimon11 Oct. 21 at 1:06 AM
$TVTX 50 sooner than you think
0 · Reply
Ruffy__
Ruffy__ Oct. 20 at 5:41 PM
$TVTX Crazy stat this ticker is completely off the radar. Whatever, this will climb without cheering crowds =)
1 · Reply
Drashkawisha
Drashkawisha Oct. 20 at 4:12 PM
$TVTX Solid base with FILSPARI already approved & selling. Now aiming for the FSGS expansion PDUFA (Jan 13, 2026). Remember the PROTECT trial? Head-to-head win vs standard of care! Rock-solid data. Building a kidney disease leader step-by-step
0 · Reply
Drashkawisha
Drashkawisha Oct. 17 at 8:31 AM
$TVTX Classic risk-off day. The entire biotech sector ($XBI) is getting hit on macro inflation fears, not on fundamentals. This is the noise that shakes out weak hands. It doesn't change the clinical data, the unmet need, or the PDUFA dates for high-conviction plays. Using this manufactured fear as a discount to add to core positions. The thesis remains unchanged.
0 · Reply
Drashkawisha
Drashkawisha Oct. 16 at 9:53 AM
$TVTX The AdCom Waiver De-Risked Everything The bull thesis for $TVTX got a massive boost with the AdCom waiver for its Jan. 13 PDUFA. The FDA doesn't see a need to debate the data for Filspari's expansion into FSGS. This is a huge vote of confidence. The regulatory comeback story is real. Holding my 130 shares strong into this high-probability event
0 · Reply
Drashkawisha
Drashkawisha Oct. 16 at 5:02 AM
$TVTX https://finance.yahoo.com/news/makes-travere-tvtx-strong-buy-160003786.html
0 · Reply
Smellmahass
Smellmahass Oct. 15 at 1:42 AM
$TGTX $AUPH $TVTX So TVTX used surrogate endpoint then? Why are analysts believe this will get approved?
0 · Reply
Latest News on TVTX
3 Potential Biotech Acquisition Targets

Sep 19, 2025, 12:53 PM EDT - 5 weeks ago

3 Potential Biotech Acquisition Targets

AZN ETNB INCY MLYS SNDX


Travere Therapeutics: Compelling FILSPARI Growth Is Hard To Ignore

Aug 12, 2025, 12:15 PM EDT - 2 months ago

Travere Therapeutics: Compelling FILSPARI Growth Is Hard To Ignore


DeadInvestor
DeadInvestor Oct. 27 at 4:14 PM
$TVTX Average analyst estimates are $104.6 million. Whats everyone’s view here? It would be nice for TVTX to beat estimates here.
0 · Reply
DeadInvestor
DeadInvestor Oct. 24 at 4:39 PM
$TVTX What value do we assign to this Chugai Japan deal (Renalys) royalties?
0 · Reply
Drashkawisha
Drashkawisha Oct. 21 at 11:25 AM
$TVTX hidden gem
0 · Reply
Dimon11
Dimon11 Oct. 21 at 1:06 AM
$TVTX 50 sooner than you think
0 · Reply
Ruffy__
Ruffy__ Oct. 20 at 5:41 PM
$TVTX Crazy stat this ticker is completely off the radar. Whatever, this will climb without cheering crowds =)
1 · Reply
Drashkawisha
Drashkawisha Oct. 20 at 4:12 PM
$TVTX Solid base with FILSPARI already approved & selling. Now aiming for the FSGS expansion PDUFA (Jan 13, 2026). Remember the PROTECT trial? Head-to-head win vs standard of care! Rock-solid data. Building a kidney disease leader step-by-step
0 · Reply
Drashkawisha
Drashkawisha Oct. 17 at 8:31 AM
$TVTX Classic risk-off day. The entire biotech sector ($XBI) is getting hit on macro inflation fears, not on fundamentals. This is the noise that shakes out weak hands. It doesn't change the clinical data, the unmet need, or the PDUFA dates for high-conviction plays. Using this manufactured fear as a discount to add to core positions. The thesis remains unchanged.
0 · Reply
Drashkawisha
Drashkawisha Oct. 16 at 9:53 AM
$TVTX The AdCom Waiver De-Risked Everything The bull thesis for $TVTX got a massive boost with the AdCom waiver for its Jan. 13 PDUFA. The FDA doesn't see a need to debate the data for Filspari's expansion into FSGS. This is a huge vote of confidence. The regulatory comeback story is real. Holding my 130 shares strong into this high-probability event
0 · Reply
Drashkawisha
Drashkawisha Oct. 16 at 5:02 AM
$TVTX https://finance.yahoo.com/news/makes-travere-tvtx-strong-buy-160003786.html
0 · Reply
Smellmahass
Smellmahass Oct. 15 at 1:42 AM
$TGTX $AUPH $TVTX So TVTX used surrogate endpoint then? Why are analysts believe this will get approved?
0 · Reply
Drashkawisha
Drashkawisha Oct. 14 at 6:56 PM
$TVTX we might end green today...
0 · Reply
Drashkawisha
Drashkawisha Oct. 14 at 12:09 PM
0 · Reply
Drashkawisha
Drashkawisha Oct. 13 at 1:47 PM
$TVTX is quietly building momentum. FILSPARI is already on the market, with expansion into FSGS and broader IgAN populations underway. Clinical data has been consistent, cash position solid (~$320M), and current valuation still doesn’t reflect the full commercial potential. Underrated setup.
0 · Reply
FloatTrip
FloatTrip Oct. 10 at 3:53 AM
0 · Reply
Drashkawisha
Drashkawisha Oct. 9 at 5:22 AM
$TVTX FINANCIAL FORTRESS & DILUTION PROTECTION Zero Dilution Risk: TVTX holds over $319 Million in cash and generates substantial revenue from its existing approved drug (FILSPARI for IgAN). This financial stability eliminates the risk of a pre-PDUFA dilution, a critical Playbook requirement. Safety Net: The company is fully funded for the commercial launch and R&D. DE-RISKED REGULATORY PATHWAY PDUFA Target: January 13, 2026 (for the FSGS indication). The De-Risking Event: The FDA has waived the Advisory Committee (AdCom) for this application. This is a powerful signal of the FDA's confidence in the data and removes a major source of regulatory uncertainty.
0 · Reply
RunnerSignals
RunnerSignals Oct. 6 at 8:20 PM
market warriors flip green $QBTS $LAES $IONQ $QSI $TVTX started red but charged back strong into the close! real comeback energy today
0 · Reply
Drashkawisha
Drashkawisha Oct. 6 at 5:53 PM
$TVTX deep dive into the $TVTX January 16, 2026 Call Options Chain reveals strong market conviction and a massive hype trade being set up ahead of the PDUFA binary event. The largest concentration of Open Interest (OI) is found at the $30.00 Strike Call (with over 1,900 contracts). This volume acts as a powerful signal, suggesting that the options market views $30.00 as the minimum expected floor price post-approval. The "Hype Trade" (Ask Price Breakeven): The aggressive traders are loading up on the deep out-of-the-money (OTM) calls: The $40.00 Call for Jan 16, 2026, has an Ask Price of $7.50. This means traders are paying a premium, and the stock must hit $47.50 ($40.00 Strike + $7.50 Premium) just to break even on the trade. Conclusion: The options market is aggressively pricing in a major rally. While $30.00 is the high-confidence floor, the active trading in OTM strikes suggests a potential upside target of $47.50 is being actively set by risk-takers.
0 · Reply
DARKP00L
DARKP00L Oct. 6 at 5:11 PM
$TVTX 13:02 on Oct. 06 2025 Travere Therapeutics shares are trading higher. Guggenheim issued a Buy rating on the stock and a price target of $47. #tradeideas
0 · Reply
Ruffy__
Ruffy__ Oct. 6 at 2:47 PM
0 · Reply
DylanGFM
DylanGFM Oct. 3 at 2:26 AM
$TVTX ready with $SENS
0 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 4:07 AM
$TVTX: Unusual Options Activity Alerted PUT flow observed 398x contracts at Strike price of $20 Exp on 11/21/2025 with Premium of $34K and showing BEARISH Sentiment
0 · Reply
111ggg
111ggg Sep. 30 at 2:38 PM
$TVTX interesting action
0 · Reply